These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35549623)

  • 1. Outpatient treatment options to address the SARS-CoV-2 variant Omicron.
    McCarthy MW
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1129-1133. PubMed ID: 35549623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Preliminary Genomic Analysis of the Omicron Variants of SARS-CoV-2 in Central India During the third wave of the COVID-19 Pandemic.
    Singh P; Negi SS; Bhargava A; Kolla VP; Arora RD
    Arch Med Res; 2022 Sep; 53(6):574-584. PubMed ID: 36123226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity.
    Mohsin M; Mahmud S
    Medicine (Baltimore); 2022 May; 101(19):e29165. PubMed ID: 35583528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
    Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
    J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico.
    Castelán-Sánchez HG; Martínez-Castilla LP; Sganzerla-Martínez G; Torres-Flores J; López-Leal G
    Virus Evol; 2022; 8(2):veac109. PubMed ID: 36582501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
    Xia S; Wang L; Zhu Y; Lu L; Jiang S
    Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.
    CDC COVID-19 Response Team
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(50):1731-1734. PubMed ID: 34914670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Spread of SARS-CoV-2 Variant Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion.
    Grabowski F; Kochańczyk M; Lipniacki T
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological Characterization of Patients in the First Eight Weeks Following Detection of SARS-CoV-2 B.1.1.529 (omicron) Variant in Cuba.
    Pérez-Santosa L; Kourí-Cardellá V; Tejero-Suárez Y; Macías-Roig LM; Pintos-Saavedra Y; Medero-Díaz D; Figueredo-Amador C; Naranjo-González C; Morales-Arredondo D; Tamayo-Pérez NE; Martínez-Montesino Y; López-Almaguer Y; de Armas-Fernández JR; Portal-Miranda JA; Guzmán-Tirado MG
    MEDICC Rev; 2022 Oct; 24(3-4):18-23. PubMed ID: 36417330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2.
    Brüssow H
    Microb Biotechnol; 2022 Jul; 15(7):1927-1939. PubMed ID: 35443078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
    Molina KC; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    Int J Infect Dis; 2023 Jul; 132():34-39. PubMed ID: 37072054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.
    Hui KPY; Ho JCW; Cheung MC; Ng KC; Ching RHH; Lai KL; Kam TT; Gu H; Sit KY; Hsin MKY; Au TWK; Poon LLM; Peiris M; Nicholls JM; Chan MCW
    Nature; 2022 Mar; 603(7902):715-720. PubMed ID: 35104836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates.
    Lundberg AL; Lorenzo-Redondo R; Hultquist JF; Hawkins CA; Ozer EA; Welch SB; Prasad PVV; Achenbach CJ; White JI; Oehmke JF; Murphy RL; Havey RJ; Post LA
    JMIR Public Health Surveill; 2022 Jun; 8(6):e37377. PubMed ID: 35500140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Cases of Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections Caused by the Omicron Variant (B.1.1.529 Lineage) in International Travelers to Japan.
    Maruki T; Iwamoto N; Kanda K; Okumura N; Yamada G; Ishikane M; Ujiie M; Saito M; Fujimoto T; Kageyama T; Saito T; Saito S; Suzuki T; Ohmagari N
    Clin Infect Dis; 2022 Aug; 75(1):e354-e356. PubMed ID: 34979547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
    Flisiak R; Zarębska-Michaluk D; Rogalska M; Kryńska JA; Kowalska J; Dutkiewicz E; Dobrowolska K; Jaroszewicz J; Moniuszko-Malinowska A; Rorat M; Podlasin R; Tronina O; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1279-1285. PubMed ID: 36001284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.